NICE backs Opdivo for classical Hodgkin lymphoma
admin 2nd June 2017 Uncategorised 0Patients with classical Hodgkin lymphoma (cHL) living in England and Wales could now become the first to get routine access on the NHS to Bristol-Myers Squibb’s immunotherapy Opdivo after a u-turn saw cost regulators provisionally back the drug.
More: NICE backs Opdivo for classical Hodgkin lymphoma
Source: News